The stock of Sarepta Therapeutics Inc (NASDAQ: SRPT) has increased by 0.74 when compared to last closing price of 135.04.Despite this, the company has seen a gain of 7.41% in its stock price over the last five trading days. InvestorPlace reported 2024-05-04 that Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untreatable conditions.
Is It Worth Investing in Sarepta Therapeutics Inc (NASDAQ: SRPT) Right Now?
The price-to-earnings ratio for Sarepta Therapeutics Inc (NASDAQ: SRPT) is 2045.71x, which is above its average ratio. Moreover, the 36-month beta value for SRPT is 0.96. Analysts have varying opinions on the stock, with 11 analysts rating it as a “buy,” 6 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SRPT is 88.89M and currently, short sellers hold a 5.48% of that float. On May 08, 2024, SRPT’s average trading volume was 876.77K shares.
SRPT’s Market Performance
SRPT’s stock has seen a 7.41% increase for the week, with a 7.64% rise in the past month and a 7.62% gain in the past quarter. The volatility ratio for the week is 5.75%, and the volatility levels for the past 30 days are at 3.94% for Sarepta Therapeutics Inc. The simple moving average for the past 20 days is 9.43% for SRPT’s stock, with a 21.07% simple moving average for the past 200 days.
Analysts’ Opinion of SRPT
Many brokerage firms have already submitted their reports for SRPT stocks, with BMO Capital Markets repeating the rating for SRPT by listing it as a “Outperform.” The predicted price for SRPT in the upcoming period, according to BMO Capital Markets is $170 based on the research report published on January 31, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see SRPT reach a price target of $113. The rating they have provided for SRPT stocks is “Buy” according to the report published on December 13th, 2023.
Deutsche Bank gave a rating of “Buy” to SRPT, setting the target price at $109 in the report published on December 12th of the previous year.
SRPT Trading at 8.19% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.92% of loss for the given period.
Volatility was left at 3.94%, however, over the last 30 days, the volatility rate increased by 5.75%, as shares surge +7.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.17% lower at present.
During the last 5 trading sessions, SRPT rose by +7.41%, which changed the moving average for the period of 200-days by +28.50% in comparison to the 20-day moving average, which settled at $124.78. In addition, Sarepta Therapeutics Inc saw 41.08% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Murray Dallan, who sale 3,635 shares at the price of $140.00 back on May 02 ’24. After this action, Murray Dallan now owns 18,125 shares of Sarepta Therapeutics Inc, valued at $508,900 using the latest closing price.
Boor Kathryn Jean, the Director of Sarepta Therapeutics Inc, sale 761 shares at $122.93 during a trade that took place back on Mar 11 ’24, which means that Boor Kathryn Jean is holding 7,516 shares at $93,550 based on the most recent closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.88 for the gross margin
The net margin for Sarepta Therapeutics Inc stands at 0.01. The total capital return value is set at -0.04. Equity return is now at value 2.02, with 0.54 for asset returns.
Based on Sarepta Therapeutics Inc (SRPT), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at -0.43. The debt to equity ratio resting at 1.29. The interest coverage ratio of the stock is 43.96.
Currently, EBITDA for the company is -267.82 million with net debt to EBITDA at -18.0. When we switch over and look at the enterprise to sales, we see a ratio of 9.84. The receivables turnover for the company is 3.35for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.05.
Conclusion
To wrap up, the performance of Sarepta Therapeutics Inc (SRPT) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
